Total circulating cell-free miRNA in plasma as a predictive biomarker of the thyroid diseases

Basit Öğe Kaydı
dc.authoridCaglar Cil, ozge/0000-0001-8737-2891
dc.authoridCAYIR, AKIN/0000-0002-2014-6635
dc.contributor.authorCaglar, Ozge
dc.contributor.authorCayir, Akin
dc.date.accessioned2025-01-27T20:45:33Z
dc.date.available2025-01-27T20:45:33Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackgroundThyroid cancer is a common endocrine cancer. Great progress has been made in resolving its molecular mechanisms in recent years. The molecular changes observed in thyroid cancer can be used as biomarkers for diagnostic, prognostic and therapeutic purposes. MicroRNAs (miRNAs) are important components in biological and metabolic pathways, such as developmental stages, signal transduction, cell maintenance, and differentiation. Hence, their malfunctioning can expose humans to malignancies. miRNA expressions have been shown to be dysregulated in different tumor types, like thyroid cancer, and may cause tumor initiation and progression. In previous studies, only cancer has been studied, and miRNA has been detected from the tissues in all the studies performed. In this study, we have focused on thyroid diseases such as bening nodules and Hashimoto's disease, which might be the cause of thyroid cancer, and have carried out miRNA tests in the blood samples taken from the arms thyroid patients. Material and methodThe present study was conducted on the blood samples of 100 thyroid patients. Of the 100 patients in our study, 33 consisted of patients with thyroiditis, while 37 patients were diagnosed with benign thyroid nodules and 30 patients had thyroid cancer. For the control group, 18 patients were included. The plasma samples were analyzed, and the total miRNA levels were determined. ResultsWe found that the ccf-miRNA amount of benign patients is significantly lower than that of the controls. Similarly, the miRNA amount in the controls is significantly higher than that of the thyroiditis (P=0.06) and the malign groups miRNA (P=0.084). Although the present study has a low number of patients, the plasma samples could be used as a source of circulating miRNAs. In addition, the total miRNA of thyroid diseases could be used as a biomarker for different types of thyroid diseases. We could suggest, for future study, that specific miRNAs in bodily fluid might show specific properties to be used as biomarkers of thyroid diseases.
dc.identifier.doi10.1002/jcb.28173
dc.identifier.endpage9022
dc.identifier.issn0730-2312
dc.identifier.issn1097-4644
dc.identifier.issue6
dc.identifier.pmid30506793
dc.identifier.scopus2-s2.0-85057972880
dc.identifier.scopusqualityQ1
dc.identifier.startpage9016
dc.identifier.urihttps://doi.org/10.1002/jcb.28173
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24628
dc.identifier.volume120
dc.identifier.wosWOS:000467135600020
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Cellular Biochemistry
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectcancer
dc.subjectdiagnosis
dc.subjectmiRNA
dc.subjectprognosis
dc.subjectthyroid disease
dc.titleTotal circulating cell-free miRNA in plasma as a predictive biomarker of the thyroid diseases
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu